Traumatic hyphemaMANAGEMENT

TRAUMA PRESENTATIONS · 12 SECTIONS

⚲

355 items

☷ Legend

01Approach to the Critical Patient/attcp37

Immediate threats

›Vision-threatening triage

›Open globe concern

›Eye shield

›Nothing by mouth if surgery possible

›Avoid tonometry if open globe concern

›Globe rupture red flags

›Teardrop pupil

›360 degree subconjunctival hemorrhage

›Extruded uveal tissue

›Retrobulbar hemorrhage risk

›Proptosis

›Tight eyelids

›Decreased vision

›Severe pain with nausea

›High intraocular pressure concern

›Early antiemetic strategy

Monitoring and goals

›Clinical targets

›Visual acuity as baseline marker

›Each eye separately

›Pin-hole if available

›Intraocular pressure only if globe integrity assured

›Target pressure plan set with ophthalmology

›Lower threshold for intervention in sickle cell disease or trait

›Head of bed elevation

›30 to 45 degrees

›Minimizes corneal endothelial exposure to blood

Early consultation and escalation

›Ophthalmology involvement

›Immediate consultation triggers

›Total hyphema

›Hyphema grade III or IV

›Intraocular pressure elevation

›Sickle cell disease or trait

›Anticoagulant use

›Co-injury escalation

›Suspected orbital fracture

›Suspected intraocular foreign body

›Suspected retinal detachment

02History/hx33

Mechanism and timeline

›Event profile

›Mechanism category

›Blunt trauma

›Penetrating trauma

›Post-surgical or iatrogenic mechanism

›Timing

›Time of injury

›Symptom progression

›Rebleed window risk

›Day 2 to day 5 after injury

›Larger secondary bleed risk

Symptom pattern

›Ocular symptoms

›Visual changes

›Blurred vision

›Transient obscurations

›Pain and photophobia

›Ciliary spasm features

›Worsening with light

›Nausea or vomiting

›High intraocular pressure correlation

›Need for antiemetic plan

Risk factors and modifiers

›Patient factors

›Sickle cell status

›Sickle cell disease history

›Sickle cell trait history

›Bleeding tendency

›Anticoagulants

›Antiplatelets

›Known coagulopathy

›Prior ocular history

›Glaucoma

›Prior hyphema

›Prior ocular surgery

03Physical Exam/exam32

Core eye exam

›Baseline ocular assessment

›Visual acuity

›Each eye separately

›Near and distance if feasible

›Pupils

›Size and reactivity

›Afferent pupillary defect

›Extraocular movements

›Diplopia

›Pain with movement

Slit lamp and anterior segment

›Anterior segment findings

›Hyphema characterization

›Layered blood height estimate

›Microhyphema

›Hyphema grade

›Grade I less than one third anterior chamber

›Grade II one third to one half anterior chamber

›Grade III more than one half less than total

›Grade IV total hyphema

›Associated findings

›Corneal abrasion

›Traumatic iritis

Pressure and posterior segment

›Pressure and fundus strategy

›Intraocular pressure

›Only if no open globe concern

›Trend plan if elevated

›Fundus view

›Red reflex quality

›Limited view prompts imaging plan

›PITFALLS

›Gonioscopy deferred in acute period

›Scleral depression avoided early

04Differential Diagnosis/ddx27

Life threats and vision threats

›High-risk ocular trauma

›Open globe injury

›Full thickness corneal or scleral laceration

›Ruptured globe

›Retrobulbar hemorrhage with orbital compartment syndrome

›Proptosis

›Elevated intraocular pressure with tight orbit

›Retinal detachment

›Flashes and floaters

›Curtain vision loss

Common mimics and co-injuries

›Anterior segment conditions

›Traumatic iritis

›Cells and flare

›Photophobia out of proportion

›Corneal abrasion

›Foreign body sensation

›Fluorescein uptake

›Lens injury

›Lens subluxation

›Traumatic cataract

›Posterior segment hemorrhage

›Vitreous hemorrhage

›Hazy view

›Sudden floaters

›Retinal hemorrhage

›Blunt trauma patterns

›Commotio retinae

05Laboratory Tests/lt18

Bleeding and medication assessment

›Hemorrhage risk labs

›Complete blood count for bleeding concern

›Hemoglobin baseline

›Platelet count

›Coagulation profile if anticoagulant use

›INR

›aPTT

Sickle cell testing

›Hemoglobinopathy evaluation

›Sickle cell status clarification

›Known disease documentation

›Known trait documentation

›If status unknown and risk ethnicity or history

›Hemoglobin electrophoresis pathway

›Local rapid screen if available

Targeted testing for associated trauma

›Trauma adjuncts

›Pregnancy test if imaging planned and pregnancy possible

›Urine or serum beta hCG

›Imaging risk discussion support

06Diagnostic Tests/dt34

Scoring Systems

›Grading and prognostic tools

›Hyphema grading scale

›Grade I less than one third anterior chamber

›Grade II one third to one half anterior chamber

›Grade III more than one half less than total

›Grade IV total hyphema

›Ocular Trauma Score framework

›Initial visual acuity category

›Globe rupture variable

›Endophthalmitis variable

›Perforating injury variable

›Retinal detachment variable

MRI

›Orbit MRI role

›Limited indications

›Occult soft tissue injury with nondiagnostic CT

›Nonmetallic foreign body consideration when CT equivocal

›Contraindications

›Suspected metallic intraocular foreign body

›Unstable trauma patient

›CT orbit without contrast

›Indications

›Suspected orbital fracture

›Suspected intraocular foreign body

›Interpretation targets

›Orbital wall fracture

›Foreign body density

›Globe contour abnormality

Ultrasound

›Ocular ultrasound considerations

›Contraindication

›Open globe concern

›Pressure on globe risk

›Uses when globe integrity confirmed

›Vitreous hemorrhage evaluation

›Retinal detachment evaluation

07Disposition/dispo17

Admission and observation

›Higher acuity criteria

›Admission considerations

›Hyphema grade III or IV

›Total hyphema

›Elevated intraocular pressure

›Sickle cell disease or trait

›Social and adherence considerations

›Inability to comply with activity restriction

›Lack of reliable follow-up in 24 hours

Discharge pathway

›Outpatient criteria

›Low-risk features

›Small hyphema or microhyphema

›Stable visual acuity

›Intraocular pressure acceptable for plan

›Follow-up plan

›Ophthalmology review within 24 hours

›Daily or near-daily reassessment during rebleed window

08Treatment/t71

Protective and positioning measures

›Conservative measures

›Eye protection

›Rigid eye shield

›No eye patch with pressure

›Positioning

›Head elevation 30 to 45 degrees

›Upright as tolerated during waking

›Activity restriction

›Avoid heavy lifting

›Avoid bending and Valsalva

Analgesia and antiemetics

›Symptom control

›Pain control options

›Acetaminophen oral 10 to 15 mg/kg per dose

›Maximum 75 mg/kg/day

›Adult maximum 4 g/day

›If severe pain

›Short-acting opioid per local protocol

›Avoid oversedation masking neurologic trauma

›Nausea prevention

›Ondansetron oral dissolving tablet 4 mg

›Repeat every 8 hours as needed

›Pediatric dosing 0.15 mg/kg

Cycloplegics and steroids

›Anterior chamber stabilization

›Cycloplegic options

›Cyclopentolate 1 percent

›1 drop three times daily

›Reduces ciliary spasm pain

›Atropine 1 percent

›1 drop twice daily

›Longer duration option

›Topical corticosteroid options

›Prednisolone acetate 1 percent

›1 drop every 4 to 6 hours

›Taper per ophthalmology response

Intraocular pressure control

›Pressure lowering ladder

›First-line topical agents

›Timolol 0.5 percent

›1 drop twice daily

›Avoid in severe asthma or bradycardia

›Brimonidine 0.2 percent

›1 drop three times daily

›Avoid in infants

›Carbonic anhydrase inhibitors

›Dorzolamide 2 percent

›1 drop three times daily

›Avoid or use with caution in sickle cell disease or trait

›Acetazolamide oral 500 mg

›Initial dose per ophthalmology for significant elevation

›Avoid in sickle cell disease or trait

›Hyperosmotic therapy options

›Mannitol IV 0.5 to 1 g/kg

›Use for severe elevation per ophthalmology

›Caution in heart failure and renal impairment

Antifibrinolytics

›Rebleed reduction strategy

›Tranexamic acid oral 25 mg/kg

›Every 8 hours

›Maximum 1500 mg per dose

›Aminocaproic acid oral 50 to 100 mg/kg

›Every 4 hours while awake

›Adult maximum 30 g/day

›Use pattern

›Consider for higher-grade hyphema per ophthalmology

›Thrombosis risk review before use

Surgical escalation

›Operative indications

›Anterior chamber washout triggers

›Persistent total hyphema

›Corneal blood staining

›Intraocular pressure uncontrolled with maximal medical therapy

›Sickle cell disease or trait lower thresholds

›Earlier washout consideration

›Earlier intervention at lower pressure levels

09Special Populations/sp21

Pregnancy

›Pregnancy considerations

›Medication selection

›Prefer topical agents with minimal systemic absorption

›Avoid systemic carbonic anhydrase inhibitors unless specialist-directed

›Imaging strategy

›CT only if clear trauma indication

›Shielding and dose minimization

Geriatric

›Older adult factors

›Anticoagulants and antiplatelets

›INR evaluation if warfarin

›Coordination for reversal decisions

›Comorbidity constraints

›Beta blocker drops caution with conduction disease

›Hyperosmotics caution with cardiac and renal disease

Pediatrics

›Pediatric management

›Adherence challenges

›Higher admission consideration for unreliable positioning

›Shield compliance issues

›Medication safety

›Avoid brimonidine in infants

›Weight-based dosing for analgesics and antiemetics

10Background/b27

Epidemiology

›Frequency and course

›Common after blunt eye trauma

›Higher incidence in children and adolescents

›Sports and projectiles common mechanisms

›Secondary hemorrhage pattern

›Highest risk day 2 to day 5

›Reported rebleed ranges vary widely across studies

Pathophysiology

›Bleeding mechanism

›Iris and ciliary body vessel disruption

›Shearing forces from blunt trauma

›Direct vessel injury with penetrating trauma

›Pressure consequences

›Trabecular meshwork obstruction by red cells

›Intraocular pressure elevation risk

Therapeutic Considerations

›Why core therapies work

›Head elevation

›Settling of blood inferiorly

›Reduced corneal staining risk

›Cycloplegia

›Reduces iris movement

›Reduces pain from ciliary spasm

›Topical steroids

›Reduces inflammation and synechiae risk

›Monitoring for steroid response pressure rise

›Sickle cell disease or trait

›Higher risk of pressure elevation

›Greater likelihood of requiring surgical intervention

11Patient Discharge Instructions/pdi21

copy discharge instructions

›Home care plan

›Eye protection

›Wear rigid eye shield at all times except drops

›No contact lenses until cleared

›Position and activity

›Sleep with head elevated 30 to 45 degrees

›Avoid sports and heavy lifting

›Medication cautions

›Avoid aspirin

›Avoid ibuprofen and other NSAIDs

›Return to ED now

›Worsening vision

›New severe blurring

›New curtain or field loss

›Increasing pain or headache

›With nausea or vomiting

›Concern for high intraocular pressure

›New flashing lights or many floaters

›Retinal tear or detachment concern

›Re-injury to the eye

›Any new trauma to the affected eye

12References/r17

Clinical guidelines and evidence-based sources

›Core sources

›American Academy of Ophthalmology hyphema management pearls

›Eye shield and activity limitation recommendations

›Head elevation recommendation

›EyeWiki hyphema overview

›Surgical intervention proportion estimate

›Monitoring during first several days guidance

›Evidence reviews and background

›NCBI Bookshelf StatPearls hyphema review

›Mechanism of injury and pathophysiology summary

›Complication overview

›Cochrane style review of traumatic hyphema interventions

›Steroids and cycloplegics as common practice patterns

›Antifibrinolytic evidence discussion

›Sickle cell trait hyphema outcomes studies

›Higher risk of elevated intraocular pressure

›Increased surgical intervention frequency

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed June 16, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.